Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) Return on Assets (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Return on Assets for 13 consecutive years, with 20.19% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Assets fell 350.0% year-over-year to 20.19%, compared with a TTM value of 20.19% through Nov 2025, down 350.0%, and an annual FY2025 reading of 12.6%, down 1032.0% over the prior year.
  • Return on Assets was 20.19% for Q4 2025 at CNBX Pharmaceuticals, down from 14.67% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.76% in Q2 2021 and bottomed at 20.19% in Q4 2025.
  • Average Return on Assets over 5 years is 5.46%, with a median of 3.11% recorded in 2022.
  • The sharpest move saw Return on Assets skyrocketed 179bps in 2023, then tumbled -1498bps in 2024.
  • Year by year, Return on Assets stood at 1.46% in 2021, then plummeted by -118bps to 3.17% in 2022, then skyrocketed by 46bps to 1.71% in 2023, then plummeted by -878bps to 16.69% in 2024, then decreased by -21bps to 20.19% in 2025.
  • Business Quant data shows Return on Assets for CNBX at 20.19% in Q4 2025, 14.67% in Q3 2025, and 5.62% in Q2 2025.